Kyverna Therapeutics, Inc. KYTX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.2%

Gilead SciencesGILD

$98M+5.4%

Climb Bio, Inc.CLYM

$38K—

Artiva Biotherapeutics, Inc.ARTV

$692K+8.0%

Iovance Biotherapeutics, Inc.IOVA

$3.78M+11.3%

Allogene TherapeuticsALLO

$2.87M-7.4%

FAQ

What is Kyverna Therapeutics, Inc.'s D&A?

Kyverna Therapeutics, Inc. (KYTX) reported D&A of $351K in Q1 2026.

How has Kyverna Therapeutics, Inc.'s D&A changed year-over-year?

Kyverna Therapeutics, Inc.'s D&A decreased by 29.9% year-over-year, from $501K to $351K.

What is the long-term trend for Kyverna Therapeutics, Inc.'s D&A?

Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s D&A has grown at a 2.7% compound annual growth rate (CAGR), from $1.71M to $1.8M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.